MichaelLevyMDPhD

Neurology • Boston, MA

Neuroimmunology/Multiple Sclerosis

Massachusetts General Hospital/Harvard Medical School

Join to view full profile

Dr. Levy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Levy's full profile

Already have an account?

Office
55 Fruit St
Boston, MA 02114
Phone+1 617-726-7565

Summary

Dr. Michael Levy is a Neurologist based in Boston, MA, with a subspecialty in Neuroimmunology/Multiple Sclerosis. He completed his Neurology residency, Neuroimmunology & Multiple Sclerosis fellowship, and Internal Medicine internship at Johns Hopkins University. He currently serves as an Associate Professor at Massachusetts General Hospital. Prior to this, he also served as an Associate Professor at Johns Hopkins Hospital. In addition to general neurology, Dr. Levy also possesses experience in multiple sclerosis and neuromyelitis optica. He has several publications under his name and has participated in multiple clinical trials.

Education & Training

Johns Hopkins UniversityFellowship, Neuroimmunology & Multiple Sclerosis, 2008 - 2009
Johns Hopkins UniversityResidency, Neurology, 2005 - 2008
Johns Hopkins UniversityInternship, Internal Medicine, 2004 - 2005
Baylor College of MedicineClass of 2004

Certifications & Licensure

MA State Medical License 2018 - 2025
ME State Medical License 2023 - 2025
NH State Medical License 2023 - 2025
MD State Medical License 2006 - 2024
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

K08 Mentored Clinical Scientist Research Career Development Award National Institutes of Health, NINDS, 2013

Clinical Trials

Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial Siderosis Start of enrollment: 2012 Mar 01
Completed
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis Start of enrollment: 2012 Jul 01
C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Start of enrollment: 2013 Jan 01
Completed
Phase 1
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Start of enrollment: 2013 Jun 01
Completed
Phase 1
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) Start of enrollment: 2014 Apr 11
Terminated
Phase 3
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Start of enrollment: 2015 Jan 12
Completed
Phase 3
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Start of enrollment: 2014 Feb 01
Completed
Phase 2
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders Start of enrollment: 2015 Apr 01
Completed
Phase 2, Phase 3
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Start of enrollment: 2016 Jan 01
Completed
Phase 1
Scrambler Trial for Pain in NMOSD Start of enrollment: 2018 Feb 21
Completed
Not Applicable
Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis Start of enrollment: 2022 Sep 15
Withdrawn
Phase 2
Roles: Principal Investigator, Contact
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD Start of enrollment: 2023 Nov 03
Recruiting
Not Applicable
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Development and validation of a claims-based algorithm to identify patients with Neuromyelitis Optica Spectrum disorder.
Anisha M Patel, Alex Exuzides, Irina Yermilov, Hannah Dalglish, Sarah N Gibbs
Journal of the Neurological Sciences. 2024-08-15
Can placebo-controlled phase 2 disease-modifying therapy trials in MS still be justified?
Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, Michael Levy, E Ann Yeh
Multiple Sclerosis and Related Disorders. 2024-07-01
1 citations
Role of C5 inhibitors in neuromyelitis optica spectrum disorders with seropositive anti-aquaporin-4 antibody: A systematic review and meta-analysis.
Seraj Makkawi, Hassan K Salamatullah, Ahmed Alkhiri, Dania E Faidah, Lena M Afif
Multiple Sclerosis and Related Disorders. 2024-05-01

Press Mentions

Changemakers in Rare: Becca SalkySeptember 23rd, 2024
Transition to Inebilizumab Treatment Linked to Suppression of NMOSD AttacksMay 22nd, 2024
Massachusetts Is Calling for a Curfew to Curb Rising COVID-19 Infections. Experts Say It's Probably Not EnoughNovember 6th, 2020
Join now to see all